[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rem-sleep-behavior-disorder-irbd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rem-sleep-behavior-disorder-irbd":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,52,82,124,172,200,226,252],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100629446","understanding-alpha-synuclein-spread-in-parkinsons-disease-through-blood-biomarkers-and-neuroimaging-100629446",false,"NCT07474779","Understanding Alpha-Synuclein Spread in Parkinson's Disease Through Blood Biomarkers and Neuroimaging","From Genes to Virtual Brain: Defining the Pathogenic Mechanisms Promoting Alfa-synuclein Seeding and Spreading in Parkinson's Disease.","SYNchronPD","Inclusion criteria for Parkinson's disease cohorts (GBA-PD and nonGBA-PD):\n\n* Diagnosis of PD according to MDS-PD criteria and, for the GBA-PD group, presence of heterozygous GBA mutations (with a balanced distribution of severe, risk, mild, and complex variants);\n* Disease duration between 3 and 7 years;\n* Disease stage according to Hoehn \\& Yahr ≤ 3;\n* Absence of mutations in other known genes associated with PD susceptibility;\n* Age \\> 18 Years;\n* Ability to understand and voluntarily sign informed consent and to comply with study procedures.\n\nExclusion criteria for Parkinson's disease cohorts:\n\n* Diagnosis of atypical and\u002For secondary parkinsonism;\n* Diagnosis of dementia according to DSM-5 criteria;\n* Presence of other neurological disorders and\u002For essential tremor;\n* Presence of systemic inflammatory or infectious diseases, autoimmune diseases, or malignant tumors at the time of enrollment.\n\nInclusion criteria for unaffected subjects (GBA-nonPD and nonGBA-nonPD):\n\n* Age \\> 18 Years;\n* Ability to understand and voluntarily sign informed consent and to comply with study procedures;\n* No diagnosis of PD or other neurological disorders;\n* Presence of a heterozygous GBA mutation for the GBA-nonPD group and absence of such mutation for control subjects (nonGBA-nonPD);\n* Absence of mutations in other known genes associated with PD susceptibility.\n\nExclusion criteria for unaffected subjects (GBA-nonPD and nonGBA-nonPD):\n\n* Presence of systemic inflammatory or infectious diseases, autoimmune diseases, or malignant tumors at the time of enrollment;\n* Diagnosis of atypical and\u002For secondary parkinsonism;\n* Diagnosis of dementia according to DSM-5 criteria.\n\nInclusion criteria for subjects with idiopathic REM Sleep Behavior Disorder (GBA-iRBD and nonGBA-iRBD):\n\n* Diagnosis of idiopathic REM Sleep Behavior Disorder according to ICSD-3;\n* Age \\> 18 Years;\n* Ability to understand and voluntarily sign informed consent and to comply with study procedures;\n* No diagnosis of PD or other neurological disorders;\n* Presence of a heterozygous GBA mutation for the GBA-iRBD group and absence of such mutation for the nonGBA-iRBD group;\n* Absence of mutations in other known genes associated with PD susceptibility.\n\nExclusion criteria for subjects with idiopathic REM Sleep Behavior Disorder (GBA-iRBD and nonGBA-iRBD):\n\n* Presence of systemic inflammatory or infectious diseases, autoimmune diseases, or malignant tumors at the time of enrollment;\n* Diagnosis of atypical and\u002For secondary parkinsonism;\n* Diagnosis of dementia according to DSM-5 criteria.",true,"ALL","18 Years",{"count":21,"type":22},160,"ESTIMATED","INTERVENTIONAL",[25],"NA","The project aims to investigate how abnormal accumulation of alpha synuclein and its interaction with tau influence brain function across the Parkinson's disease (PD) spectrum, with particular focus on individuals carrying GBA1 mutations. This interventional, monocentric, cross sectional study includes patients with PD, individuals with idiopathic REM sleep behavior disorder, and participants without PD.\n\nAll enrolled subjects will undergo clinical and neuropsychological assessments, blood based biomarker analyses related to neurodegeneration, synaptic and mitochondrial function, and multimodal brain MRI to evaluate brain structure, white matter integrity, and functional connectivity.\n\nThe study aims to:\n\n* characterize the relationship between alpha synuclein\u002Ftau pathology and synaptic mitochondrial dysfunction;\n* identify biomarker and connectivity signatures across disease stages and genetic backgrounds;\n* integrate preclinical, clinical, biological, and imaging data to support the development of mechanistic models of alpha synuclein propagation.\n\nIn parallel, preclinical studies in GBA PD mouse models and wild type mice will be used to investigate how changes in PD-related pathology (alpha-synuclein and tau) relates to behavior, brain imaging alterations and mitochondrial, axonal and synaptic damage. Animal model will also aid the validation of a new PET tracer that targets alpha synuclein (i.e., \\[¹⁸F\\]Syntacasyn).\n\nTogether, human and preclinical studies are designed to provide a translational framework integrating molecular changes with brain network alterations and clinical heterogeneity in PD.",[28,29,30],"Parkinson's Disease (PD)","GBA1 Parkinson Disease","REM Sleep Behavior Disorder (iRBD)",[32,33,34,35,36,37,38],"GBA1 carriers","Brain Connectivity","Virtual Brain","Extracellular vesicles","Mitochondrial Dysfunction","Mice Models","Translational Science","NOT_YET_RECRUITING","2026-04-27",{"date":42,"type":43},"2026-05-01","ACTUAL",{"date":45,"type":22},"2026-05-11",{"date":47,"type":22},"2029-02",{"name":49,"class":50},"University of Pavia","OTHER",2,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100621049","pain-assessment-in-patients-with-idiopathic-rapid-eye-movement-rem-sleep-behaviour-disorder-100621049","NCT07365566","Pain Assessment in Patients With Idiopathic Rapid Eye Movement (REM) Sleep Behaviour Disorder","Pain Assessment in Patients With Idiopathic REM Sleep Behaviour Disorder","PAIN-iRBD","Inclusion criteria:\n\n* Diagnosed with iRBD confirmed by polysomnography;\n* No clinical diagnosis of Parkinson's disease or other diagnosis of neurodegenerative disease;\n* Ability to understand and complete study procedures and questionnaires;\n\nControl group:\n\n* Diagnosed with narcolepsy type 1;\n* Coexisting REM sleep behavior disorder confirmed by polysomnography;\n* Ability to understand and complete study procedures and questionnaires;\n\nExclusion Criteria:\n\n* Diagnosed Parkinson's Disease, dementia with Lewy bodies or multiple system atrophy;\n* Severe depression according to Diagnostic and Statistical Manual of Mental Disorders (DSM V);\n* Inability to complete study procedures or questionnaires.",{"count":61,"type":22},24,[25],"Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, with over 12 million patients expected globally by 2040. The disease is currently diagnosed at the appearance of motor symptoms, but by then, over 60% of striatal dopaminergic neurons have already been destroyed. Prodromal symptoms such as idiopathic REM Sleep Behavior Disorder (iRBD), anosmia, mood disorders and constipation appear earlier and are listed as criteria for a prodromal PD diagnosis. Identifying early signs is critical to initiate neuroprotective treatments as early as possible. While pain is prevalent and highly disabling in early PD, no data are currently available on pain perception in iRBD patients, whose condition is of the main risk factor for PD development.",[30,65],"Narcolepsy Type 1",[67,68,69,70,71,72],"parkinson","REM sleep","pain","REM sleep behavior disorder","narcolepsy Type 1","sleep","RECRUITING",{"date":42,"type":43},{"date":76,"type":43},"2026-02-24",{"date":78,"type":22},"2026-08",{"name":80,"class":50},"University Hospital, Toulouse",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":17,"sex":18,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":100,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":81},"100633985","the-swedish-biofinder-sleep-study-100633985","NCT07533799","The Swedish BioFINDER Sleep Study","BioFINDER-Sleep: Idiopathic REM-sleep Behavior Disorder & Early Parkinson's Disease","Inclusion Criteria:\n\nIdiopathic RBD:\n\n* Polysomnography verified RBD according to AASM criteria.\n* Does not fulfill diagnostic criteria for idiopathic Parkinson´s disease.\n* Age range 50-100. Women who are \\\u003C55 years of age will be required to take a pregnancy test before participation in the PET and scintigraphy part of the study if not post-menopausal.\n* Ability to give informed consent.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEarly Parkinson´s disease:\n\n* Fulfills the diagnostic criteria for idiopathic Parkinson´s disease.\n* The PD patients will be de novo (yet without any PD treatment) or with treatment for a maximum of 3 years.\n* Age range 50-100. Women who are \\\u003C55 years of age will be required to take a pregnancy test before participation in the PET and scintigraphy part of the study if not post-menopausal.\n* Ability to give informed consent.\n* Speaks Swedish fluently as stated above. Healthy Controls\n* Age range 50-100. Women who are \\\u003C55 years of age will be required to take a pregnancy test before participation in the PET and scintigraphy part of the study if not post-menopausal.\n* No diagnosis of PD or another significant neurological disorder.\n* No diagnosis of RBD.\n* Ability to give informed consent.\n* Speaks Swedish fluently as stated above.\n\nExclusion Criteria:\n\nFor all groups:\n\n* Past history of severe or repeated concussive head injury or stroke or any significant systemic disease or unstable medical condition.\n* History of severe and unstable depression, schizophrenia, schizoaffective disorder or bipolar disorder.\n* Significant white matter microvascular disease.\n* Contraindication to MRI and PET.\n\nExclusion criteria specific for early Parkinson´s disease:\n\n* Normal dopamine transporter (\\[18F\\]FE-PE2I) scan.","50 Years","100 Years",{"count":92,"type":22},650,"OBSERVATIONAL","BioFINDER-Sleep study was established in 2021 and will include patients with early Parkinson´s disease (PD) and persons with iRBD to provide essential insights into the underlying mechanisms of the progressive neurodegenerative processes in central and peripheral nervous systems. Briefly polysomnography will be used to establish the presence of RBD in both the early PD cohort and in the iRBD cohort. Then, state of the art multimodal imaging techniques will be used, including, magnetic resonance imaging (MRI), positron emission tomography (PET) of the dopamine transporters (DAT-PET) to quantify dopamine terminal loss, and \\[123I\\] MIBG scintigraphy of the heart will be performed to quantify the loss noradrenaline terminals to the heart. In addition to this, synuclein seed amplification assays (SSAs) will be applied to cerebrospinal fluid (CSF) and skin samples to establish synuclein pathology status. Further, CSF and blood biomarkers will be developed that can be used to as prognostic markers. These investigations will be done in parallel to clinical assessments of motor and non-motor symptoms as well as assessment of cognitive function in a longitudinal setting.",[96,30,97,98,99],"Parkinson´s Disease","Lewy Body Disease","Synucleinopathy","Synucleinopathies",[101,102,103,104,105,106,107,108,109,110,111,112,113,114],"Early diagnosis","CSF","Plasma","PET","MRI","DAT PET","Smell test","synuclein seed amplification assays","MIBG","Polysomnography","α-synuclein","Motoric test","cognitive test","UPDRS","2026-04-09",{"date":117,"type":43},"2026-04-16",{"date":119,"type":43},"2021-10-01",{"date":121,"type":22},"2033-06",{"name":123,"class":50},"Skane University Hospital",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":135,"conditions":136,"keywords":146,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":81},"100632087","ultra-high-resolution-pet-in-aging-neurodegeneration-and-psychotic-disorders-100632087","NCT07509125","Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders","Ultra-High Resolution PET of the Human Brain and Spinal Cord in Healthy Aging, Dementia, Movement Disorders, ALS and Psychotic Disorders","Inclusion Criteria:\n\n* WP1: Healthy controls\n* Age between 18 and 90 years old (15 aged 18-50 years and 25 aged 50 90 years);\n* Subject is judged to be in good health by the investigator on the basis of medical history, physical examination including vital signs and clinical laboratory tests;\n* No history or evidence of current major neurological, internal or psychiatric disorder, based on the medical assessment as described hereabove and neuropsychological assessment;\n* No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline;\n* In subjects \\\u003C 60 years of age, a normal structural MRI scan as assessed by expert radiologist.\n* In subjects \\>= 60 years of age white matter hyperintensities corresponding to a WML (white matter lesion) score \\\u003C= 2 (of 3) on the Age-Related White Matter changes scale are acceptable;\n* When older than 50 years of age, the volunteer is willing to undergo a p- tau217 blood sample.\n* WP2: Dementia\n* Patient has a clinical diagnosis of biomarker-proven prodromal AD\n* WP3: ALS spectrum\n* Subject must meet El Escorial Criteria (30) and Awaji-Shima criteria (31) for at least possible ALS;\n* WP4: Movement disorders\n* (all): Patient (or legal representative, when applicable) is able to understand the patient information form and give written informed consent.\n* Parkinson´s disease (PD):\n* Patient has clinically established PD based on the Movement Disorder Society (MDS) diagnostic criteria (32);\n* Patient has an abnormal 18F-PE2I PET;\n* No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline.\n* Multiple system atrophy (MSA)\n* Patient has clinically established or clinically probable MSA-P based on the\n* Movement Disorder Society (MDS) diagnostic criteria (33);\n* Patient has an abnormal 18F-PE2I PET.\n* Progressive supranuclear palsy (PSP)\n* Patient has an abnormal 18F-PE2I PET;\n* Patient has clinically established probable PSP according to the latest MDS criteria\n* Dementia with Lewy bodies (DLB)\n* Patient has probable DLB by consensus criteria (cognitive impairment MoCA \\\u003C 26 + visual hallucinations and\u002For fluctuating alertness);\n* Patient has an abnormal 18F-PE2I PET.\n* Idiopathic REM sleep behavior disorder (iRBD)\n* Patient has Polysomnography-confirmed iRBD;\n* No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline;\n* No clinical evidence of parkinsonism at baseline.\n* WP5: Psychosis\n* DSM 5 criteria for a non-affective schizophrenia spectrum psychotic disorder;\n* Age between 18 and 55 years old for adult-onset psychosis, onset of psychosis (and age) above 60 years old for very late onset psychosis.\n\nExclusion Criteria:\n\n* Subject has a history of any major (other) internal, psychiatric or neurological disease that may interfere with the investigations (especially liver and kidney disease, uncontrolled diabetes, cancer, severe depression, stroke, severe TBI);\n* Subject is currently a user (including recreational use) of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse;\n* Subject chronically uses medication that has central nervous system effects (e.g. strong painkillers such as opioids, neuroleptics,..; ) (other than prescribed for the illness in case of patients);\n* Subject has had exposure to ionizing radiation (\\> 1 mSv) in other research studies within the last 12 months;\n* Subject has a contra-indication for MRI scanning;\n* Subject suffers from claustrophobia or cannot tolerate confinement during PET-MRI scanning procedures; subject cannot lie still for (at least) 60 minutes inside the scanner;\n* (For subjects with arterial sampling): The subject is hypersensitive to lidocaine (used for local anaesthesia during the placement of the arterial catheter), has an abnormal Allen test (a test to check blood flow in the arteries of the forearm) or is on anti-coagulant therapy;\n* Subject (or his\u002Fher legal representative) does not understand the study procedures;\n* Subject is unwilling or unable to perform all of the study procedures, or is considered unsuitable in any way by the principal investigator;\n* Subject is potentially pregnant (hCG test can be done if doubt exists).","90 Years",{"count":133,"type":22},300,[25],"The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and psychiatric disorders such as Alzheimer's disease (AD), Parkinson's disease and related movement disorders, amyotrophic lateral sclerosis (ALS), and psychotic disorders. Researchers will use the NeuroExplorer PET\u002FCT system, a new scanner that can show very small structures in the brain and spinal cord in much more detail than regular PET.\n\nThe main questions this study aims to answer are:\n\n* How do small but important brain regions (like the locus coeruleus, substantia nigra, and thalamic nuclei) change in healthy aging?\n* What early brain changes occur in neurodegenerative and psychotic disorders, and can they help improve early diagnosis?\n\nParticipants will:\n\n* Undergo PET and MRI brain scans using different tracers that measure brain metabolism (18F-FDG), synaptic density (¹⁸F-SynVesT-1), dopamine transporters (¹⁸F-PE2I), and tau protein buildup (¹⁸F-MK6240).\n* Complete cognitive and clinical assessments related to memory, mood, and motor or psychiatric symptoms, depending on their group.\n\nThis study will include healthy volunteers and patients with mild cognitive impairment due to Alzheimer´s disease, ALS, Parkinson's disease and related disorders, or psychotic disorders.\n\nThe results will help create detailed brain imaging maps for healthy aging and identify early biomarkers for different diseases to support better diagnosis and treatment in the future.",[137,138,139,30,140,141,142,143,144,145],"Alzheimer Dementia (AD)","ALS - Amyotrophic Lateral Sclerosis","Parkinson s Disease","PSP - Progressive Supranuclear Palsy","MSA - Multiple System Atrophy","Dementia With Lewy Bodies (DLB)","ALS With Frontotemporal Dementia (ALS\u002FFTD)","Adult Onset Psychotic Disorder","Very Late Onset Psychotic Disorder",[147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162],"PET\u002FCT scan","Alzheimer´s disease","Dementia","Amyotrophic Lateral Sclerosis","Parkinson´s disease","REM sleep behavior disorders","Progressive supranuclear palsy","Multiple System Atrophy","Dementia with Lewy Bodies","Psychotic disorders","Schizophrenia","ALS with frontotemporal dementia","UHR PET","Locus coeruleus","Papez circuit","Thalamic subnuclei","2026-03-27",{"date":165,"type":43},"2026-04-03",{"date":167,"type":43},"2026-02-13",{"date":169,"type":22},"2029-09",{"name":171,"class":50},"Universitaire Ziekenhuizen KU Leuven",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":23,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":199},"100560820","study-of-sleep-disorders-in-prodromal-and-definite-parkinsons-disease-100560820","NCT06582121","Study of Sleep Disorders in Prodromal and Definite Parkinsons Disease","Controlled, Multicenter Study of Sleep Disorders in Prodromal and Definite Parkinsons Disease","SOMPARK","Inclusion Criteria:\n\nCommon to all groups:\n\n* Age superior 18 years\n* Patients who have received complete information about the study from an investigator and who fully consent to participate.\n\nFor Parkinson Disease (PD):\n\n* Patients followed for PD diagnosed according to international criteria for the diagnosis of PD (MDS criteria),\n* A MoCA score greater than 20\u002F30\n* No treatment with deep brain stimulation.\n\nFor REM Sleep Behavior Disorder (RBD):\n\n* Diagnosis of RBD according to ICSD-3 criteria: presence on polysomnography of an abnormal elevation of muscle tone during REM sleep (more than 18% of REM sleep without chin atonia) and\u002For the presence of REM sleep behaviors on video-polysomnography,\n* Absence of progressive neurodegenerative pathology: absence of diagnostic criteria for PD, multiple system atrophy, or Lewy body dementia.\n\nFor healthy controls:\n\n\\- No neurological or psychiatric disease\n\nExclusion Criteria:\n\nCommon to all groups:\n\n* Pregnant or breastfeeding women\n* Subjects under guardianship\u002Fconservatorship\n* Persons deprived of liberty.",{"count":181,"type":22},457,[25],"Multicenter controlled study of sleep disorders in isolated REM Behavior Disorder and Parkinson\\'s disease (SOMPARK)",[185,30],"Parkinson Disease",[187,188,189],"Parkinson disease","isolated RBD","Sleep","2026-03-04",{"date":192,"type":43},"2026-03-06",{"date":194,"type":43},"2025-03-18",{"date":196,"type":22},"2028-04",{"name":198,"class":50},"Assistance Publique - Hôpitaux de Paris",6,{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":23,"phases":209,"briefSummary":210,"conditions":211,"keywords":212,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":81},"100620301","role-of-slow-waves-in-the-progression-of-neurodegeneration-in-isolated-rem-sleep-behavior-disorder-100620301","NCT07355842","Role of Slow Waves in the Progression of Neurodegeneration in Isolated REM Sleep Behavior Disorder","SloW-iRBD","Inclusion Criteria:\n\n* Signed informed consent\n* Diagnosis of polysomnography-confirmed isolated REM Sleep Behavior Disorder (iRBD) based on international criteria (ICSD-3), combined with EITHER\n* UPDRS III without action tremor ≥ 4 AND abnormal olfaction, OR\n* diagnosis of PD along international criteria for less than 2 years\n\nFurther inclusion criteria are:\n\n* no dopaminergic treatment and no foreseen start of such treatment during duration of the study\n* ability to apply the intervention, alone or with help of a co-habitant, stable living situation\n* sufficient language skills in German, French or Italian\n* negative pregnancy test for women of child-bearing potential\n\nExclusion Criteria:\n\n* Suspected or known non-compliance to other therapies\n* current or recent participation in another clinical trial\n* extended absences\n* hearing impairment that prevents hearing the tones for auditory stimulation\n* non-responder to auditory stimulation during screening\n* clinically significant concomitant disease or unstable condition\n* Apnea-Hypopnea-Index (AHI) \\> 15\u002Fh or under Continuous Positive Airway Pressure (CPAP) treatment\n* Restless Legs Syndrome\n* meeting criteria for diagnosis of atypical Parkinson syndrome\n* diagnosis of Dementia or Montreal Cognitive Assessment (MoCA) \\\u003C 24\n* severe Depression or other psychiatric disorder\n* regular use of benzodiazepines and other central nervous system depressant substances\n* current or recent history within the last year of substance abuse disorders or chronic alcohol consumption\n* recent or planned major surgery\n* history of allergies and hypersensitivity relevant for electrode application or medication allergies\n* additional exclusion criteria for PET imaging\n* any criterion that may pose the participant at risk\n* breastfeeding, intention to become pregnant, or unwillingness to use medically reliable contraception for women of child-bearing potential",{"count":208,"type":22},80,[25],"This study tests whether enhancing deep sleep with gentle sounds at night can slow progression in people with iRBD or early Parkinson's disease. Participants wear a sensor headband and headphones for 18 months. Four assessments including mobility, memory, imaging (PET\u002FMRI), lumbar puncture, and blood tests are assessed.",[185,30],[213,187,189,214,215,216,70],"Parkinson","Neurodegeneration","Auditory stimulation","iRBD","2026-02-16",{"date":219,"type":43},"2026-02-17",{"date":221,"type":43},"2026-01-15",{"date":223,"type":22},"2029-06-30",{"name":225,"class":50},"University of Zurich",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":234,"briefSummary":235,"conditions":236,"keywords":241,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":81},"100620722","development-and-online-evaluation-of-an-online-course-for-parasomnias-100620722","NCT07361315","Development and Online Evaluation of an Online Course for Parasomnias","Inclusion Criteria:\n\n* physician referred for parasomnia\n* meet criteria for parasomnia on the Structured Clinical Interview for Sleep Disorders (SCISD-R)\n* age \\>= 18 years\n* parasomnia duration \\>= 6 months\n* English reading, sighted\n* access to device.\n\nExclusion Criteria:\n\n* currently taking one of Lithium, Thioridazine, Chlorpromazine, Perphenazine, Methaqualone, Amitriptyline, Selective Serotonin Re-Uptake Inhibitors, Serotonin and Norepinephrine Re-Uptake inhibitors, or Zopiclone\n* seizure or major neurological disorder\n* untreated sleep apnea, restless legs syndrome, or narcolepsy",{"count":233,"type":22},20,[25],"Parasomnias are unwanted events during sleep. These refer to sleep terrors, sleepwalking, sleep eating, nightmares, and movement during REM sleep. There are few systematic behavioral treatments for these problems and individuals with them often receive little education about self-management. This research examines and evaluates the effectiveness of a 4 week online course providing education and guidance about managing parasomnias. The primary outcomes are improvement in parasomnia frequency and distress. The secondary outcomes are improvements in work and social adjustment, mood, anxiety, stress level, fatigue, sleepiness, insomnia, and cognitive interference.",[237,238,239,30,240],"Sleep Terror","Sleepwalking","Nightmare Disorder","Confusional Arousal",[242,243],"Parasomnia course evaluation","online parasomnia",{"date":245,"type":43},"2026-01-23",{"date":247,"type":43},"2025-11-14",{"date":249,"type":22},"2026-12-31",{"name":251,"class":50},"University of Manitoba",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":17,"sex":18,"minAge":89,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":81},"100455034","molecular-imaging-of-inflammation-in-parkinsons-disease-using-lps-and-tspo-petmr-100455034","NCT05205291","Molecular Imaging of Inflammation in Parkinson's Disease Using LPS and TSPO-PET\u002FMR","Molecular Imaging of LPS-induced Microglial Activation in Parkinson's Disease (PD). A TSPO PET-MR Imaging Study","Inclusion Criteria (all):\n\n* 50-85 years of age, male or female\n* Able to give informed consent\n* Adequate visual and auditory acuity to complete the neuropsychological testing\n* No presence or history of significant neurological or psychiatric disorders\n* BDI ≥ 20, moderate depression\n* No presence or history of inflammatory or autoimmune disorders\n* Negative family history for neurodegenerative diseases\n* Cognitively healthy (i.e., education-adjusted MoCA total score ≥ 26 points at screening)\n* Female subjects must either be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or post-menopausal for at least 1 year (no menses for 12 months without an alternative medical cause) or if they are of childbearing potential, they must commit to use of a highly effective contraceptive measure for the duration of the study and a minimum of six months following the PET scan (including combined \\[estrogen and progestogen containing\\] hormonal contraception associated with inhibition of ovulation \\[oral, intravaginal, or transdermal\\], progestogen-only hormonal contraception associated with inhibition of ovulation \\[oral, injectable, or implantable\\], intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner or sexual abstinence).\n* Male subjects and their partners of childbearing potential must commit to the use of a highly effective method of contraception during the study and for a minimum of three months following each PET scan (including, for female partners of childbearing potential, combined \\[estrogen and progestogen containing\\] hormonal contraception associated with inhibition of ovulation \\[oral, intravaginal, or transdermal\\], progestogen-only hormonal contraception associated with inhibition of ovulation \\[oral, injectable, or implantable\\], intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, male subjects with vasectomy or sexual abstinence).\n* Male subjects must commit to not donate sperm during the study and for a minimum of three months after the last PET scan.\n* Individuals must commit to refrain from drinking alcohol for 48 hours before each visit, refrain from drinking any caffeinated substance for 12 hours before the PET-MR visits, and to refrain from smoking or using any nicotine-containing products on the day of the PET-MR scans.\n* Individuals must commit to not donating blood up to three months after the last PET scan.\n* Individuals must commit to come to the screening and Day 1 visits in a fasting state (i.e., minimum of 8 hours since last meal\u002Ffood intake).\n* Individuals must commit to not to take any over-the-counter non-steroidal anti-inflammatory drugs or drink alcohol for 48h before screening visit.\n\nInclusion Criteria (Parkinson's disease patients):\n\n* 50-85 years of age, male or female\n* Able to give informed consent\n* Adequate visual and auditory acuity to complete the neuropsychological testing\n* No presence or history of other significant neurological or psychiatric disorders\n* Diagnosis of PD according to the Movement Disorder Society Clinical Diagnostic Criteria (Postuma et al., Mov Disord 2015)\n* Drug-naïve participants with PD must have a diagnosis of PD but must be therapy-free at the time of enrolment\n* For participants with PD-MCI: diagnosis of MCI according the diagnostic criteria for MCI-PD (Level I; Litvan et al., Mov Disord 2012) and\u002For MoCA \\\u003C 23\n* For participants with PD taking dopaminergic therapy: must be in stable therapy (i.e. not have changed therapy in the last 60 days)\n* Female subjects must either be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or post-menopausal for at least 1 year (no menses for 12 months without an alternative medical cause) or if they are of childbearing potential, they must commit to use of a highly effective contraceptive measure for the duration of the study and a minimum of six months following the PET scan (including combined \\[estrogen and progestogen containing\\] hormonal contraception associated with inhibition of ovulation \\[oral, intravaginal, or transdermal\\], progestogen-only hormonal contraception associated with inhibition of ovulation \\[oral, injectable, or implantable\\], intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner or sexual abstinence).\n* Male subjects and their partners of childbearing potential must commit to the use of a highly effective method of contraception during the study and for a minimum of three months following each PET scan (including, for female partners of childbearing potential, combined \\[estrogen and progestogen containing\\] hormonal contraception associated with inhibition of ovulation \\[oral, intravaginal, or transdermal\\], progestogen-only hormonal contraception associated with inhibition of ovulation \\[oral, injectable, or implantable\\], intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, male subjects with vasectomy or sexual abstinence).\n* Male subjects must commit to not donate sperm during the study and for a minimum of three months after the last PET scan.\n* Individuals must commit to refrain from drinking alcohol for 48 hours before each visit, refrain from drinking any caffeinated substance for 12 hours before the PET-MR visits, and to refrain from smoking or using any nicotine-containing products on the day of the PET-MR scans.\n* Individuals must commit to not donating blood up to three months after the last PET scan.\n* Individuals must commit to come to the screening and Day 1 visits in a fasting state (i.e., minimum of 8 hours since last meal\u002Ffood intake).\n* Individuals must commit to not to take any over-the-counter non-steroidal anti-inflammatory drugs or drink alcohol for 48h before screening visit.\n\nFor participants with iRBD:\n\nInclusion criteria:\n\n* 40-85 years of age, male or female\n* Able to give informed consent\n* Adequate visual and auditory acuity to complete the neuropsychological testing\n* No presence or history of significant neurological or psychiatric disorders\n* BDI-II ≥ 20, moderate depression\n* No presence or history of inflammatory or autoimmune disorders\n* Negative family history for neurodegenerative diseases\n* Cognitively healthy (i.e., education-adjusted MoCA total score ≥ 26 points at screening)\n* Female subjects must either be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or post-menopausal for at least 1 year (no menses for 12 months without an alternative medical cause) or if they are of childbearing potential, they must commit to use of a highly effective contraceptive measure for the duration of the study and a minimum of six months following the PET scan (including combined \\[estrogen and progestogen containing\\] hormonal contraception associated with inhibition of ovulation \\[oral, intravaginal, or transdermal\\], progestogen-only hormonal contraception associated with inhibition of ovulation \\[oral, injectable, or implantable\\], intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner or sexual abstinence).\n* Male subjects and their partners of childbearing potential must commit to the use of a highly effective method of contraception during the study and for a minimum of three months following each PET scan (including, for female partners of childbearing potential, combined \\[estrogen and progestogen containing\\] hormonal contraception associated with inhibition of ovulation \\[oral, intravaginal, or transdermal\\], progestogen-only hormonal contraception associated with inhibition of ovulation \\[oral, injectable, or implantable\\], intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, male subjects with vasectomy or sexual abstinence).\n* Male subjects must commit to not donate sperm during the study and for a minimum of three months after the last PET scan.\n* Individuals must commit to refrain from drinking alcohol for 48 hours before each visit, refrain from drinking any caffeinated substance for 12 hours before the PET-MR visits, and to refrain from smoking or using any nicotine-containing products on the day of the PET-MR scans.\n* Individuals must commit to not donating blood up to three months after the last PET scan.\n* Individuals must commit to come to the screening and Day 1 visits in a fasting state (i.e., minimum of 8 hours since last meal\u002Ffood intake).\n* Individuals must commit to not to take any over-the-counter non-steroidal anti-inflammatory drugs or drink alcohol for 48h before screening visit.\n\nExclusion Criteria (all):\n\n* Unwilling and\u002For unable to cooperate with study procedures\n* Current or a recent (\\\u003C12 months) history of drug or alcohol abuse\u002Fdependence\n* BDI ≥ 20, moderate depression\n* Presence of clinically significant (as deemed by the study physician) alterations on safety laboratory blood and urine testing\n* Presence of comorbidities or concomitant medications incompatible with the assessment or imaging procedures as deemed by the study physician\n* Recent (less than 30 days) use of antipsychotics and corticosteroids\n* Recent (less than 2 days) use of NSAIDs.\n* Use of any long-acting benzodiazepines (e.g., diazepam) or use of slow or medium acting benzodiazepines with doses ≥ 30 mg within 30 days prior to the first imaging scan.\n* Presence of rs6971 genotype of low-affinity binders that hinders the measure of microglial activation with \\[11C\\]PBR28 PET\n* Presence of neurological disorders and known intracranial co-morbidities such as stroke, haemorrhage, space-occupying lesions, signs of inflammation of the CNS\n* Presence of serology compatible with HIV, syphilis, SARS-CoV2, or viral hepatitis\n* History of autonomic dysfunction, previous vasovagal syncope or a positive tilt-test, and with bradycardia or use of medications causing bradycardia (e.g. beta-blockers)\n* Pregnancy or breastfeeding\n* Contraindication to MRI, such as presence of metal devises or implants, metal deposited in the body, or metal grains in the eyes\n* History of cancer within the last 5 years, except for appropriately treated, non-melanoma skin carcinoma, non-metastatic prostate cancer, treated carcinoma in situ of the cervix or Stage I uterine cancer.\n* Claustrophobia or history of back pain that makes prolonged laying on the PET or MRI scanner intolerable\n* Contraindication to arterial cannulation, such as history of bleedings, haemorrhage, etc.\n* Negative Allen's test (i.e. absence of collateral flow on hands on the test)\n* Recent (less than 30 days) infection or vaccination (e.g. flu, SARS-CoV2 etc.)\n* Concurrent participation to any clinical trial testing investigational drugs\n\nExclusion Criteria (Parkinson's disease patients):\n\n* Unwilling and\u002For unable to cooperate with study procedures\n* Current or recent history of drug or alcohol abuse\u002Fdependence\n* BDI ≥ 20, moderate depression\n* Presence of clinically significant (as deemed by the study physician) alterations on safety laboratory blood or urine testing\n* Presence of comorbidities or concomitant medications incompatible with the assessment or imaging procedures as deemed by the study physician\n* Recent (less than 30 days) use of antipsychotics and corticosteroids.\n* Recent (less than 2 days) use of NSAIDs.\n* Use of any long-acting benzodiazepines (e.g., diazepam) or use of slow or medium acting benzodiazepines with doses ≥ 30 mg within 30 days prior to the first imaging scan.\n* Presence of rs6971 genotype of low-affinity binders that hinders the measure of microglial activation with \\[11C\\]PBR28 PET\n* Presence of other neurological disorders and known intracranial co-morbidities such as stroke, haemorrhage, space-occupying lesions, signs of inflammation of the CNS\n* History of autonomic dysfunction, previous vasovagal syncope or a positive tilt-test, and with bradycardia or use of medications causing bradycardia (e.g. beta-blockers)\n* Presence of serology compatible with HIV, syphilis, SARS-CoV2, or viral hepatitis\n* Pregnancy or breastfeeding\n* Contraindication to MRI, such as presence of metal devises or implants, metal deposited in the body, or metal grains in the eyes\n* History of cancer within the last 5 years, except for appropriately treated, non-melanoma skin carcinoma, non-metastatic prostate cancer, treated carcinoma in situ of the cervix or Stage I uterine cancer.\n* Claustrophobia or history of back pain that makes prolonged laying on the PET or MRI scanner intolerable\n* Contraindication to arterial cannulation, such as history of bleedings, haemorrhage, etc.\n* Negative Allen's test (i.e. absence of collateral flow on hands on the test)\n* Recent (less than 30 days) infection or vaccination (e.g. flu, SARS-CoV2 etc.)\n* Concurrent participation to any clinical trial testing investigational drugs\n\nExclusion criteria (for participants with iRBD):\n\n* Unwilling and\u002For unable to cooperate with study procedures\n* Current or a recent (\\\u003C12 months) history of drug or alcohol abuse\u002Fdependence\n* BDI-II ≥ 20, moderate depression\n* Presence of clinically significant (as deemed by the study physician) alterations on safety laboratory blood and urine testing\n* Presence of comorbidities or concomitant medications incompatible with the assessment or imaging procedures as deemed by the study physician\n* Recent (less than 30 days) use of antipsychotics and corticosteroids\n* Recent (less than 2 days) use of NSAIDs.\n* Use of any long-acting benzodiazepines (e.g., diazepam) or use of slow or medium acting benzodiazepines with doses ≥ 30 mg within 30 days prior to the first imaging scan.\n* Use of any of the following drugs that might interfere with dopamine transporter SPECT imaging: Ephedrine, ketamine, isoflurane, cocaine, methylphenidate, amphetamine of any amphetamine derivatives, mazindol, modafinil, benztropine, fentanyl, derivatives, buproprion, phentermine neuroleptics, metoclopramide, alpha methyldopa, , reserpine, .\n* Presence of rs6971 genotype of low-affinity binders that hinders the measure of microglial activation with \\[11C\\]PBR28 PET\n* Presence of neurological disorders and known intracranial co-morbidities such as stroke, haemorrhage, space-occupying lesions, signs of inflammation of the CNS\n* Presence of serology compatible with HIV, syphilis, or viral hepatitis\n* History of autonomic dysfunction, previous vasovagal syncope or a positive tilt-test, and with bradycardia or use of medications causing bradycardia (e.g. beta-blockers)\n* Pregnancy or breastfeeding\n* Contraindication to MRI, such as presence of metal devises or implants, metal deposited in the body, or metal grains in the eyes\n* History of cancer within the last 5 years, except for appropriately treated, non-melanoma skin carcinoma, non-metastatic prostate cancer, treated carcinoma in situ of the cervix or Stage I uterine cancer.\n* Claustrophobia or history of back pain that makes prolonged laying on the PET or MRI scanner intolerable\n* Contraindication to arterial cannulation, such as history of bleedings, haemorrhage, etc.\n* Negative Allen's test (i.e. absence of collateral flow on hands on the test)\n* Recent (less than 30 days) infection or vaccination (e.g. flu, SARS-CoV2 etc.)\n* Evidence of presynaptic dopaminergic denervation on \\[123I\\]FP-CIT SPECT\n* Concurrent participation to any clinical trial testing investigational drugs","85 Years",{"count":261,"type":22},30,"It is not known what causes Parkinson's disease and what makes it worsen over time. Research conducted in the past few years has highlighted the possible role of inflammation on this process but its actual mechanisms are still obscure.\n\nIn this study, the investigators aim to gain understanding on how inflammation is increased in Parkinson's disease and what are its mechanisms, by performing two Positron Emission Tomography (PET) scans using the tracer \\[11C\\]PBR28, that takes pictures of the brain highlighting the areas of inflammation, before and after the administration of a compound called Lipopolysaccharide or LPS, that is known to cause a mild degree of inflammation. The investigators will couple this study with two venous blood draws to measure the levels of circulating molecules of inflammation.",[264,185,30],"Neurodegenerative Diseases",[266,267,268,269],"Positron Emission Tomography","Inflammation","Neuroimaging","Biomarkers","2025-10-01",{"date":272,"type":43},"2025-10-07",{"date":274,"type":43},"2022-02-28",{"date":276,"type":22},"2026-08-31",{"name":278,"class":50},"University of Exeter"]